Eli Lilly, $1 Trillion

Eli Lilly has become the first pharmaceutical company to achieve a market capitalization exceeding $1 trillion. As of the close on November 21, Eli Lilly’s share price stood at $1,059.70, officially pushing its total market capitalization past $1 trillion. Lilly’s march toward the $1 trillion milestone is inextricably linked to its dominant performance in the weight-loss drug arena. In 2022, Lilly’s GLP-1/GIP dual-receptor agonist tirzepatide received its first FDA approval—for diabetes treatment; in November 2023, it gained additional FDA approval for weight management. Since the weight-loss indication was approved, Lilly’s stock price has surged over 77%, propelling its market value steadily upward. At the start of 2024, Gemma Game, healthcare strategist at Norway’s sovereign wealth fund, predicted that fewer than 1% of obese patients globally had received pharmacological treatment. Given the enormous potential market for weight-loss drugs, Novo Nordisk and Eli Lilly could become the world’s first healthcare companies to reach a $1 trillion market cap. Yet within less than a year, Lilly has drawn ever closer to that goal—while Novo Nordisk’s valuation has contracted continuously, standing at just over $200 billion as of the latest close. 01 Lilly’s Comeback Novo Nordisk is undoubtedly the earliest success story in the GLP-1 space. As early as 2017, its developed semaglutide received FDA approval for diabetes treatment; after gaining an additional weight-loss indication in 2021, semaglutide’s sales exploded, fully igniting the global GLP-1 market. Faced with this wave, Lilly—Novo Nordisk’s long-standing rival in metabolic disease—did not follow the existing technological path. Instead, it opted for a GLP-1/GIP dual-receptor agonist, sidestepping head-to-head competition with semaglutide in the single-target domain. Lilly’s ambition was evident even during clinical trials. The company proactively designed a “head-to-head” study against semaglutide, aiming to demonstrate superior efficacy through the most direct comparative data. In December 2024, Lilly announced top-line results from SURMOUNT-5, a Phase IIIb trial directly comparing tirzepatide and semaglutide. The results showed that tirzepatide achieved an average weight loss of 20.2%, significantly outperforming semaglutide’s 13.7%. Patients in the tirzepatide group lost an average of 22.8 kg, versus 15.0 kg in the semaglutide group. However, Lilly’s offensive extended far beyond the lab. Immediately following approval for weight management, the company launched a price war, setting tirzepatide’s monthly treatment cost at $1,060—roughly 20% lower than semaglutide’s then-price of $1,349. Subsequently, in early 2024, Lilly launched its direct-to-consumer platform, LillyDirect, enabling users to obtain prescriptions online for weight-loss and diabetes medications—and receive home delivery—precisely targeting the self-pay patient segment. In Q3 2025, Mounjaro (the diabetes version of tirzepatide) generated $2.97 billion in revenue outside the U.S., up from $728 million a year earlier; approximately 75% of those sales came from obese patients paying out-of-pocket. By contrast, Novo Nordisk adopted a comparatively conservative sales strategy, only launching its online pharmacy platform, NovoCare, in March 2025.

A Safe Haven Amid AI Stock Plunge! Large Pharma Stocks Approach All-Time Highs

As tech stocks face broad-based selling pressure, capital is rapidly flowing into large pharmaceutical stocks. Biopharma giants such as AbbVie and Eli Lilly have seen their share prices approach all-time highs this week—reflecting investors’ clear shift toward defensive assets amid turbulence in AI-related equities. On Thursday, the State Street SPDR Select Sector ETF for Health Care hit a record high of $177.19, rising 5.6% over the past five trading days. Simultaneously, investors flocked to consumer staples and U.S. Treasuries—the catalyst being the collective slump in AI-related stocks, fueled by mounting concerns over AI capital expenditure scale and slowing revenue growth at Anthropic. Lilly’s stock rose 3.4% on Thursday, closing at its third-highest level ever; AbbVie closed at $283.40—the second-highest close in its history, having set an all-time high of $283.48 the previous day. Neither company reported major clinical data releases or merger-and-acquisition news; their gains were driven purely by defensive capital rotation. Over the same five-day period, Gilead Sciences and Amgen rose 7.7% and 7.2%, respectively, while Merck gained 2.3%; UnitedHealth Group surged 9.1%, buoyed by strong Q3 earnings. Capital Rotation: AI Retreat, Pharma Steps Up According to MarketWatch, the high volatility of AI-related stocks is prompting investors to reassess the portfolio allocation value of large pharmaceutical companies. Their core appeal lies in stable, predictable earnings growth—achieved through sustained R&D pipeline investment and extension of core drug patent lifecycles—offering a risk-return profile starkly different from that of tech stocks. As AI-related equities come under pressure amid disputes over capital expenditures and downward revisions to growth expectations, investors are simultaneously turning to consumer staples and government bonds—highlighting the defensive attributes of the pharmaceutical sector. The State Street Health Care ETF hitting an all-time high is a direct reflection of this round of capital reallocation. Lilly stands as one of the central beneficiaries of this pharmaceutical rally. Leveraging its dominant position in the GLP-1 weight-loss drug market, Lilly has become one of the industry’s most widely recognized success stories.

Eli Lilly's Obesity Drug Strength Fuels Record Rally, Wall Street Optimism

2 days ago

Eli Lilly shares hit a record high as obesity drug sales beat profit expectations and raised the full-year revenue forecast. Analysts remain optimistic about the company's dominance in the obesity and diabetes markets despite pricing challenges.

reuters

2026-04-30

Not just GLP-1: Peptide-drug conjugate hits 5 obesity targets

2026-05-06

Eli Lilly Commits Additional $4.5 Billion Across Indiana Manufacturing Sites

2026-07-16

Asia Stocks to Track US Slide on Chipmaker Selloff: Markets Wrap

2026-08-23

Snoring, Subways and Stealth Ads: How Big Pharma Targets China's Waistline

2026-10-29

Eli Lilly's Obesity Drug Strength Fuels Record Rally, Wall Street Optimism

Eli Lilly's Obesity Drug Strength Fuels Record Rally, Wall Street Optimism

FAQ